Advice
in the absence of a submission from the holder of the marketing authorisation:
cabozantinib (Cabometyx) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice355KB (PDF)
Medicine details
- Medicine name:
- cabozantinib (Cabometyx)
- SMC ID:
- SMC2160
- Indication:
- As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published:
- 11 February 2019